Beryl Drugs Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 302214,
    "name": "Beryl Drugs",
    "stock_name": "Beryl Drugs",
    "full_name": "Beryl Drugs Ltd",
    "name_url": "stocks-analysis/beryl-drugs",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 0,
    "country_id": 34,
    "currency": "INR",
    "cmp": "24.24",
    "chg": 1.32,
    "chgp": "5.76%",
    "dir": 1,
    "prev_price": "22.92",
    "mcapval": "12.29 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524606,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE415H01017",
    "curr_date": "Aug 31, 11:05 AM",
    "curr_time": "11:06 AM",
    "last_traded_at": "Aug 31, 11:05 AM IST",
    "bse_nse_vol": "349 ",
    "exc_status": "Active",
    "traded_date": "Aug 31, 2026",
    "traded_date_str": "2026 08 31",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/beryl-drugs-302214-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Beryl Drugs Ltd Upgraded to Hold as Technicals Improve and Valuation Attractiveness Increases",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/beryl-drugs-ltd-upgraded-to-hold-as-technicals-improve-and-valuation-attractiveness-increases-4175386",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/BerylDrugsLtd_mojoScore_4175386.png",
        "date": "2026-08-31 08:02:06",
        "description": "Beryl Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 28 August 2026. This change reflects a nuanced improvement across technical indicators, valuation metrics, and financial trends, despite ongoing challenges in long-term fundamentals and market performance."
      },
      {
        "title": "Beryl Drugs Ltd Downgraded to Sell Amid Mixed Financial and Technical Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/beryl-drugs-ltd-downgraded-to-sell-amid-mixed-financial-and-technical-signals-4162005",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/BerylDrugsLtd_mojoScore_4162005.png",
        "date": "2026-08-20 08:06:01",
        "description": "Beryl Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 19 Aug 2026. This change reflects a combination of deteriorating financial trends, mixed technical signals, and valuation considerations, despite some attractive pricing metrics. The downgrade highlights concerns over the company’s long-term growth prospects and debt servicing ability amid a challenging market environment."
      },
      {
        "title": "Beryl Drugs Ltd Reports Flat Quarterly Performance Amid Mixed Financial Trends",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/beryl-drugs-ltd-reports-flat-quarterly-performance-amid-mixed-financial-trends-4150253",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/BerylDrugsLtd_fintrenddot_4150253.png",
        "date": "2026-08-12 11:00:09",
        "description": "Beryl Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, reported a flat financial performance for the quarter ended June 2026, marking a notable shift from its previously positive growth trajectory. Despite a robust 29.75% increase in net sales over the last six months, the company’s overall financial trend score has declined, prompting a reassessment of its near-term prospects."
      },
      {
        "title": "Beryl Drugs Ltd Upgraded to Hold as Technicals Improve Amid Mixed Financial Trends",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/beryl-drugs-ltd-upgraded-to-hold-as-technicals-improve-amid-mixed-financial-trends-4141141",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/BerylDrugsLtd_mojoScore_4141141.png",
        "date": "2026-08-07 08:07:12",
        "description": "Beryl Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 6 August 2026. This change reflects a nuanced improvement across technical indicators, valuation metrics, and recent financial performance, despite some lingering concerns over long-term fundamentals and profitability trends."
      },
      {
        "title": "When is the next results date for Beryl Drugs Ltd?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-beryl-drugs-ltd-4140465",
        "imagepath": "",
        "date": "2026-08-06 23:18:32",
        "description": "The next results date for Beryl Drugs Ltd is scheduled for 11 August 2026...."
      },
      {
        "title": "Beryl Drugs Ltd Downgraded to Sell Amid Mixed Financial and Technical Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/beryl-drugs-ltd-downgraded-to-sell-amid-mixed-financial-and-technical-signals-4100172",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/BerylDrugsLtd_mojoScore_4100172.png",
        "date": "2026-07-14 08:14:48",
        "description": "Beryl Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 13 July 2026. The revision reflects a combination of deteriorating technical indicators, modest financial trends, valuation considerations, and concerns over long-term quality metrics. This comprehensive analysis explores the four key parameters that triggered the downgrade and what it means for investors."
      },
      {
        "title": "Beryl Drugs Ltd Upgraded to Hold as Technicals Improve and Valuation Attracts",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/beryl-drugs-ltd-upgraded-to-hold-as-technicals-improve-and-valuation-attracts-4094552",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/BerylDrugsLtd_mojoScore_4094552.png",
        "date": "2026-07-09 08:07:30",
        "description": "Beryl Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 8 July 2026. This change reflects a combination of improved technical indicators, attractive valuation metrics, positive quarterly financial results, and rising promoter confidence, despite some lingering concerns over long-term fundamentals."
      },
      {
        "title": "Beryl Drugs Ltd Valuation Shifts to Very Attractive Amid Mixed Market Returns",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/beryl-drugs-ltd-valuation-shifts-to-very-attractive-amid-mixed-market-returns-4043133",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/BerylDrugsLtd_valuationdot_4043133.png",
        "date": "2026-06-10 08:00:32",
        "description": "Beryl Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, moving from an attractive to a very attractive rating. This change reflects a significant improvement in price metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, positioning the stock as a more compelling option relative to its historical averages and peer group."
      }
    ],
    "total": 292,
    "sid": "302214",
    "stock_news_url": "https://www.marketsmojo.com/news/beryl-drugs-302214"
  },
  "announcements": [
    {
      "caption": "Board Meeting Intimation for Approve Board Report And Other Matters Related To 33Rd Annual General Meeting Of The Company",
      "datetime": "27-Aug-2026",
      "details": "Beryl Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/09/2026 inter alia to consider and approve approve board report and other matters related to 33rd annual general meeting of the company",
      "source": "BSE"
    },
    {
      "caption": "Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011",
      "datetime": "20-Aug-2026",
      "details": "The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Sudhir Sethi",
      "source": "BSE"
    },
    {
      "caption": "Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011",
      "datetime": "19-Aug-2026",
      "details": "The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Sudhir Sethi",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Beryl Drugs Ltd Upgraded to Hold as Technicals Improve and Valuation Attractiveness Increases

2026-08-31 08:02:06

Beryl Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 28 August 2026. This change reflects a nuanced improvement across technical indicators, valuation metrics, and financial trends, despite ongoing challenges in long-term fundamentals and market performance.

Read full news article

Beryl Drugs Ltd Downgraded to Sell Amid Mixed Financial and Technical Signals

2026-08-20 08:06:01

Beryl Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 19 Aug 2026. This change reflects a combination of deteriorating financial trends, mixed technical signals, and valuation considerations, despite some attractive pricing metrics. The downgrade highlights concerns over the company’s long-term growth prospects and debt servicing ability amid a challenging market environment.

Read full news article

Beryl Drugs Ltd Reports Flat Quarterly Performance Amid Mixed Financial Trends

2026-08-12 11:00:09

Beryl Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, reported a flat financial performance for the quarter ended June 2026, marking a notable shift from its previously positive growth trajectory. Despite a robust 29.75% increase in net sales over the last six months, the company’s overall financial trend score has declined, prompting a reassessment of its near-term prospects.

Read full news article

Beryl Drugs Ltd Upgraded to Hold as Technicals Improve Amid Mixed Financial Trends

2026-08-07 08:07:12

Beryl Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 6 August 2026. This change reflects a nuanced improvement across technical indicators, valuation metrics, and recent financial performance, despite some lingering concerns over long-term fundamentals and profitability trends.

Read full news article

When is the next results date for Beryl Drugs Ltd?

2026-08-06 23:18:32

The next results date for Beryl Drugs Ltd is scheduled for 11 August 2026....

Read full news article

Beryl Drugs Ltd Downgraded to Sell Amid Mixed Financial and Technical Signals

2026-07-14 08:14:48

Beryl Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 13 July 2026. The revision reflects a combination of deteriorating technical indicators, modest financial trends, valuation considerations, and concerns over long-term quality metrics. This comprehensive analysis explores the four key parameters that triggered the downgrade and what it means for investors.

Read full news article

Beryl Drugs Ltd Upgraded to Hold as Technicals Improve and Valuation Attracts

2026-07-09 08:07:30

Beryl Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 8 July 2026. This change reflects a combination of improved technical indicators, attractive valuation metrics, positive quarterly financial results, and rising promoter confidence, despite some lingering concerns over long-term fundamentals.

Read full news article

Beryl Drugs Ltd Valuation Shifts to Very Attractive Amid Mixed Market Returns

2026-06-10 08:00:32

Beryl Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, moving from an attractive to a very attractive rating. This change reflects a significant improvement in price metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, positioning the stock as a more compelling option relative to its historical averages and peer group.

Read full news article

View All News